The role of interleukin-1b and its antagonist (diacerein) in estradiol benzoate-induced endometrial hyperplasia and atypia in female rats

34Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Endometrial hyperplasia (EH) is a common gynecological condition and may progress to carcinoma. We investigated the effect of diacerein (DIA) on estradiol benzoate (EB)-induced EH and atypia. DIA (50 mg/kg/day) was administered orally to rats for 4 weeks, in the presence or absence of EH induced by intramuscular injection of EB (60 μg/100 g) three times per week for 4 weeks. We measured levels of serum total cholesterol, uterine tissue malondialdehyde (MDA), total nitrites (NOx), superoxide dismutase (SOD) activity, caspase-3, interleukin-1b (IL-1b) immunoexpressions, and histopathology. Results showed that EB-induced EH and atypia manifested by significant increase in serum total cholesterol with increase in MDA and NOx levels. EB showed the typical histopathological changes of EH and atypia. In addition, there was reduction in SOD activity and decrease in caspase-3 immunoexpressions but increase in IL-1b immunoexpressions. DIA was able to reduce EB-induced pathological changes.

Cite

CITATION STYLE

APA

Refaie, M. M. M., & El-Hussieny, M. (2017). The role of interleukin-1b and its antagonist (diacerein) in estradiol benzoate-induced endometrial hyperplasia and atypia in female rats. Fundamental and Clinical Pharmacology, 31(4), 438–446. https://doi.org/10.1111/fcp.12285

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free